Intrexon buys Oxitech in $160M deal; Novavax chief touts mid-stage RSV vaccine;

@FierceBiotech: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology. News | Follow @FierceBiotech

@JohnCFierce: Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership. Article | Follow @JohnCFierce

@DamianFierce: Like most people, I'm waiting for Thug_BioAnalyst to weigh in before I form an opinion on anything this morning. | Follow @DamianFierce

> Intrexon has acquired Oxford University spinout Oxitech for $160 million in cash and stock. Oxitech uses genetic engineering tech to make crop-damaging or disease-spreading insects like mosquitoes sterile. "Oxitec's technology demonstrates that engineered biology can solve some of mankind's most difficult problems--many that have eluded solutions for a very long time--while exercising tremendous respect for the environment," says Intrexon CEO Randal Kirk, a big believer in the power of synthetic biology. "In particular, to be able to induce a population decline in a major disease vector and know your intervention does not propagate in the environment is an historic achievement." Release

> Novavax ($NVAX) CEO Stanley Erck isn't the least bit shy in talking up the commercial prospects for the company's mid-stage RSV vaccine. He tells Reuters the PhII vaccine could be "the largest selling vaccine in the history of vaccines in terms of revenue." Story

Medical Device News

@FierceMedDev: UPDATED with interview of CEO: TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report | Follow @FierceMedDev

@VarunSaxena2: Crowdsourcing challenge winner looking to commercialize NIH tech to diagnose brain cancer. Article | Follow @VarunSaxena2

@EmilyWFierce: Congress urges feds to probe FDA over morcellator safety concerns. More | Follow @EmilyWFierce

> Bill introduced to fix FDA's combination product regs; attorneys say it doesn't go far enough. Story

> Sisu to put emergency blood recycling device through trials later this year. Article

Pharma News

@FiercePharma: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI last week: Aprecia is building $25M plant where it will do 3D printing of drugs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Orexigen picks up new trial tab to settle Contrave dispute with partner Takeda. More | Follow @CarlyHFierce

> GSK defends low-margin strategy with a gloomy outlook for high drug prices. More

> Lilly chalks up a win for Cymbalta in first U.S. trial over withdrawal symptom claims. Article

Animal Health News

> Aratana continues to trim losses in Q2 as it focuses on animal treatments. News

> Merck to partner with National Milk Producers group on training and animal care. Report

> USDA grants conditional license to Zoetis for canine anti-itch therapy. Story

> Feds indict four with smuggling bogus pet products into the U.S. Item

> Dechra to buy control of Croatian animal vaccine maker for $56.4M. Article

Biotech IT News

> Apple's ResearchKit goes global as heart study expands into Hong Kong and U.K. Item

> IBM makes $1B bid for Merge to bolster Watson's image analytics capabilities. Report

> Teva buys majority stake in Immuneering to access genome analysis tools. More

> Illumina strikes deal to buy LIMS provider GenoLogics. Article

> FDA makes its first approval of a 3D-printed drug. Story

Pharma Marketing News

> Allergan plots Namzaric DTC campaign to shore up its Namenda defenses. Item

> Amarin case could unleash a flood of off-label promos. Report

> Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. More

> Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness. Story

> Big Pharma feeds controversy by routing big bucks to private CME. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.